Last reviewed 2026-04-23 · How we verify

Fondaparinux Injectable Product

Fondaparinux is a synthetic anticoagulant that selectively inhibits Factor Xa, preventing thrombin generation and blood clot formation.

Fondaparinux is a synthetic anticoagulant that selectively inhibits Factor Xa, preventing thrombin generation and blood clot formation. Used for Venous thromboembolism prophylaxis in orthopedic surgery, Acute deep vein thrombosis treatment, Acute pulmonary embolism treatment.

At a glance

Mechanism of action

Fondaparinux is a pentasaccharide that binds to antithrombin III, enhancing its ability to inactivate Factor Xa in the coagulation cascade. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby inhibiting clot formation without directly affecting thrombin itself. This selective mechanism provides anticoagulation with a predictable pharmacokinetic profile.

Approved indications

• Venous thromboembolism prophylaxis in orthopedic surgery
• Acute deep vein thrombosis treatment
• Acute pulmonary embolism treatment
• Acute coronary syndrome

Common side effects

• Bleeding
• Thrombocytopenia
• Injection site reactions
• Anemia

Key clinical trials

• Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
• Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia (PHASE4)
• Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
• Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
• Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.